Analyst Reiterated/Price Target Changed: GERN rating Buy by Needham
Price Target: $4>>5
Report Date: 03-15-2024
Symbol: GERN - Geron Corporation
Sector: Healthcare
Industry: Biotechnology
Analyst Reiterated/Price Target Changed: GERN rating Buy by Needham
Price Target: $4>>5
Geron Corporation (GERN)
919 EAST HILLSDALE BOULEVARD, SUITE 250
Foster City, CALIFORNIA 94025
Phone: 16504737700
Website: http://www.geron.com
CEO: Dr. John Scarlett
NASDAQ, Nasdaq Global Select
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. The company was founded in 1990 and is headquartered in Menlo Park, California.
best trading signals, best stock signal alert software, best stock trading signals, free trading signals
Good stock signals have been found on this server. That is all we know.
+1 (407) 559-7228